Provided by Tiger Trade Technology Pte. Ltd.

FibroGen

9.71
0.0000
Volume:- -
Turnover:323.61K
Market Cap:39.28M
PE:0.18
High:9.71
Open:9.71
Low:9.71
Close:9.71
52wk High:21.94
52wk Low:4.85
Shares:4.05M
Float Shares:3.62M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):53.38
EPS(LYR):-11.8895
ROE:-1015.79%
ROA:-18.42%
PB:-2.31
PE(LYR):-0.82

Loading ...

One new option listing and one option delisting on January 8th

TIPRANKS
·
Jan 08

FibroGen Inc - Kyntra Bio to Trade Under Symbol 'Kynb' January 8

THOMSON REUTERS
·
Jan 07

FibroGen Rebrands as Kyntra Bio

Reuters
·
Jan 07

FDA Grants Orphan Drug Designation to FibroGen's Roxadustat for Myelodysplastic Syndromes

Reuters
·
Dec 15, 2025

FibroGen Inc - to File Phase 3 Protocol in Q4 2025

THOMSON REUTERS
·
Dec 15, 2025

Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

THOMSON REUTERS
·
Dec 15, 2025

FibroGen to Present at Oppenheimer Movers in Rare Disease Summit

Reuters
·
Dec 03, 2025

Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)

TIPRANKS
·
Nov 11, 2025

FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties

TIPRANKS
·
Nov 11, 2025

FibroGen’s Strategic Moves and Financial Highlights

TIPRANKS
·
Nov 11, 2025

FibroGen reports Q3 EPS ($3.25), consensus ($4.01)

TIPRANKS
·
Nov 11, 2025

FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate

Benzinga
·
Nov 11, 2025

FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million

Reuters
·
Nov 11, 2025

FibroGen Inc: Q3 EPS $49.61

THOMSON REUTERS
·
Nov 11, 2025

FibroGen Inc expected to post a loss of $4.00 a share - Earnings Preview

Reuters
·
Nov 08, 2025

BRIEF-Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC Filing

Reuters
·
Nov 07, 2025

FibroGen Receives $6.4 Million Payment from AstraZeneca

TIPRANKS
·
Nov 07, 2025

FibroGen Receives $6.4 Million Payment From AstraZeneca Following China Operations Sale

Reuters
·
Nov 07, 2025

BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy

Reuters
·
Sep 25, 2025

William Blair Remains a Hold on FibroGen (FGEN)

TIPRANKS
·
Sep 24, 2025